Summary:
- Cassava Sciences expects to release top-line data from the RETHINK-ALZ Phase 3 trial by year-end 2024.
- The RETHINK-ALZ trial enrolled 804 patients, with over 635 completing the 52-week study.
- The primary endpoints are ADAS-Cog12 and ADCS-ADL, assessing cognitive and functional abilities, respectively.
- If RETHINK-ALZ fails, Cassava’s stock could trade near its book value of $3.47 per share, but favorable data presentation could still occur.
- Given the high-risk nature of Alzheimer’s drug development and past data concerns, caution is advised regarding SAVA stock.
DNY59
Cassava Sciences (NASDAQ:SAVA) is approaching the pivotal moment for its Alzheimer’s drug, simufilam. My previous thoughts on the stock have been skeptical, citing flaws in the quality of earlier-stage data (preclinical to Phase 2). The company expects topline data
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
This article is intended to provide informational content and should not be viewed as an exhaustive analysis of the featured company. It should not be interpreted as personalized investment advice with regard to "Buy/Sell/Hold/Short/Long" recommendations. The predictions and opinions presented are based on the author's analysis and reflect a probabilistic approach, not absolute certainty. Efforts have been made to ensure the information's accuracy, but inadvertent errors may occur. Readers are advised to independently verify the information and conduct their own research. Investing in stocks involves inherent volatility, risk, and speculative elements. Before making any investment decisions, it is crucial for readers to conduct thorough research and assess their financial circumstances. The author is not liable for any financial losses incurred as a result of using or relying on the content of this article.
Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.